End/ What are your thoughts on this #neurocritcare? Does this in combination with the 🍑 trial make you want to reconsider #ASM as #SeizureProphylaxis in #ICH?
@neurocritcarej
@swarnarmd
@aartisarwal
@alyssafloseldes
@caseyalbin
@JimmySuhMD
@JimSiegler
@medinariojaMD
6/ So overall, while #SeizureProphylaxis definitely made a dent on seizure frequency, the overall frequency of seizures was low
This data must be also viewed under the fact that this was a non randomized trial and #ASM use was at provider discretion
5/ Interesting findings:
👉About 1/5 patients with Lobar ICH had seizure
👉While #ASM prophylaxis ⬇️ sz frequency, age or hematoma size were NOT predictive of sz
👉5/11 patients with status were on #ASM
👉#SeizureProphylaxis did not appear to affect outcome at 3 months
4/ 300 patients from this 900 patient cohort had #LobarICH & were included, of which 143 pts got #SeizureProphylaxis
43 pts developed seizures, and 2 went into convulsive status and 11 into non-convulsive status, and all except 1 had a seizure within the first 7 days
3/ In this paper, the authors set to answer the question of whether #SeizureProphylaxis may be beneficial in some by retrospectively reviewing a prospectively collected cohort of #LobarICH patients, and more specifically its use to reduce early seizures (within 7 days)
2/ Do you routinely add #SeizureProphylaxis to #ICH patients?
Currently, the guidelines do not endorse this practice due to unclear benefit with some evidence of adverse effects (worse cognitive outcome) (Pic from AHA ICH 2022 guidelines)
1/ 👋 there #neurotwitter #neurosky #neurocritcare, as part of my @neurocritcarej #SoMeAmbassador role, today we will be breaking down the following article: link.springer.com/ar...
about #SeizureProphylaxis in #ICH
